Skip to main content
Oncotarget logoLink to Oncotarget
. 2017 Jun 27;8(26):43592. doi: 10.18632/oncotarget.18610

Correction: The PARP inhibitor olaparib enhances the sensitivity of Ewing sarcoma to trabectedin

José Luis Ordóñez, Ana Teresa Amaral, Angel M Carcaboso, David Herrero-Martín, María del Carmen García-Macías, Vicky Sevillano, Diego Alonso, Guillem Pascual-Pasto, Laura San-Segundo, Monica Vila-Ubach, Telmo Rodrigues, Susana Fraile, Cristina Teodosio, Agustín Mayo-Iscar, Miguel Aracil, Carlos María Galmarini, Oscar M Tirado, Jaume Mora, Enrique de Álava
PMCID: PMC5522172  PMID: 28672777

Present: The published funding information is incomplete.

Correct: Additional funding information is given below.

Funding

This project has received funding from the European Union’s Seventh Framework Programme for research, technological development and demonstration under grant agreement nr 602856 (EEC) and nr 278742 (EUROSARC).

Original article: Oncotarget. 2015; 6:18875-90. doi: 10.18632/oncotarget.4303


Articles from Oncotarget are provided here courtesy of Impact Journals, LLC

RESOURCES